GH Research PLC has appointed Dr. Vanina Popova as Chief Development Officer to lead the clinical development of its drug candidate GH001 for treatment-resistant depression (TRD) and postpartum depression (PPD). Dr. Popova brings over 20 years of experience from Johnson & Johnson, including leading pivotal trials for Spravato® in TRD. GH001, delivered via inhalation, showed promising Phase 2b results, and the company aims to advance it into pivotal clinical trials. This leadership change is key for GH Research's goal to develop new effective treatments for depression.
GH Research's leadership update is context for readers following health stocks. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 19:41 WIB: out of 150 priced US health stocks, 99 rose and 43 fell. Notable movers include NVAX at USD 8.96 with a 1-day change of +2.28%, COO at USD 63.52 with +2.14%, and TVTX at USD 52.57 with +1.96%.
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
